Literature DB >> 22208440

Comparison of the effect of non-antifungal and antifungal agents on Candida isolates from the gastrointestinal tract.

Farideh Siavoshi1, Atefeh Tavakolian, Alireza Foroumadi, Negar Mohammad Hosseini, Sadegh Massarrat, Shahrzad Pedramnia, Parastoo Saniee.   

Abstract

BACKGROUND: Non-antifungal drugs appear promising in treatment of opportunistic infections of Candida spp. that are often resistant to current antifungals.
METHODS: The broth macrodilution method (NCCLS M27-P document) was used to compare the antifungal activity of trifluoperazine, propranolol, and lansoprazole with that of ketoconazole and amphotericin B, using 50 yeast isolates from the GI tract. The minimum fungicidal concentrations (MFCs), resistance rates and the time required for fungicidal activity of the drugs (2 - 48 hours) were determined.
RESULTS: The most effective antifungal activity was exhibited by trifluoperazine. Its MFC was 32 µg/mL for Candida albicans (3.3% resistance) and Candida spp. (0% resistance) yeasts, and 64 µg/mL for Candida tropicalis with 10% resistance. The MFC for C. albicans and Candida spp. was comparable to that of ketoconazole. However, the time required for the inhibitory effect (6 hr) was shorter than that of ketoconazole (48 hr) or amphotericin B (24 hr). The time required for the inhibitory activity on C. tropicalis was 24 hr, which was shorter than that of ketoconazole and amphotericin B (48 hr). A considerable number (40%) of Candida spp. showed resistance to ketoconazole, and 20% of C. tropicalis showed resistance to amphotericin B. Trifluoperazine, an antipsychotic drug, exhibited effective antifungal activity with the MFC, comparable to ketoconazole (32 µg/mL). Among the three yeast groups, C. tropicalis showed resistance to trifluoperazine and amphotericin B, and Candida spp. was considerably resistant to ketoconazole.
CONCLUSION: Trifluoperazine could be considered as an alternative antifungal when encountering Candida spp. resistant to current antifungals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22208440     DOI: 012151/AIM.009

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  4 in total

1.  Chronic candidal osteomyelitis of mid face: A therapeutic dilemma.

Authors:  Rishi Bali; Parveen Sharma; Prachi Gupta; Shivani Gaba
Journal:  J Oral Biol Craniofac Res       Date:  2013-09-17

2.  In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.

Authors:  Luana Rossato; Érico S Loreto; Régis A Zanette; Francieli Chassot; Janio M Santurio; Sydney H Alves
Journal:  Folia Microbiol (Praha)       Date:  2016-02-04       Impact factor: 2.099

3.  A Yeast-Based Screening Unravels Potential Therapeutic Molecules for Mitochondrial Diseases Associated with Dominant ANT1 Mutations.

Authors:  Giulia di Punzio; Maria Antonietta Di Noia; Agnès Delahodde; Carole Sellem; Claudia Donnini; Luigi Palmieri; Tiziana Lodi; Cristina Dallabona
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

4.  Anti-infective properties of proton pump inhibitors: perspectives.

Authors:  Taciéli Fagundes da Rosa; Vitória Segabinazzi Foletto; Marissa Bolson Serafin; Angelita Bottega; Rosmari Hörner
Journal:  Int Microbiol       Date:  2021-09-03       Impact factor: 2.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.